News
Patients were treated with MIPLYFFA in a 48-month open-label extension (OLE) study following the Phase 2/3, randomized, double-blind, placebo-controlled pivotal trial. The OLE data demonstrate that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results